7月2022： On July 12, 2022, GenScript ProBio (Brian Ho-sung Min, CEO), a global CDMO, and ACT Therapeutics (Seogkyoung-Kong, CEO), developing a next-generation chimeric antigen receptor (CAR)-T cell therapy platform targeting solid cancer, announced that they had entered into a strategic partnership MOU concerning the development of a new CAR-T cell therapies. The MOU was in regard to the development of new CAR-T cell therapies. Through the use of this memorandum of understanding (MOU), GenScript ProBio and ACT Therapeutics have come to an agreement to further their collaboration in the field of cell therapy.
ACTTherapeuticsとGenScriptProBioは、ACTTherapeuticsのAdvancedCAR-T Platform（ACTプラットフォーム）の最初のパイプライン用のプラスミドとウイルスベクターの開発と生産に関する契約を締結中です。 ACTTherapeuticsの後続のパイプライン用。 この契約は、ACTTherapeuticsのAdvancedCAR-Tプラットフォームの最初のパイプライン用のプラスミドとウイルスベクターの生産を対象としています。
この合意の結果、GenScript ProBioは、ACT治療用のACTプラットフォームをサポートできるグローバルパートナーの地位に昇格しました。
ACTプラットフォームは、癌抗原を標的とするように設計された遺伝子を免疫細胞に挿入することにより、癌抗原を標的とする次世代の細胞および遺伝子治療技術です。 これらの遺伝子は、ウイルスベクターを使用して免疫細胞に送達されます。 GenScript ProBioは、高品質のウイルスベクタープロセス開発とGMP生産のためのワンストップサービスプラットフォームを備えており、どちらも細胞および遺伝子治療の開発に必要です。
ACT Therapeutics’ ACT platform is an advanced CAR-T technology that has a next-generation structure that goes beyond the second-generation CAR-T cell therapy and targets existing 血液がん. This is accomplished by overcoming the immune suppression microenvironment of solid cancer and activating the immune cells that are surrounding the cancer. Several studies have also used animals to test the ACT platform to see how well it works and if it is safe. These studies have also confirmed that the platform can be used to treat solid cancer while staying in the immunosuppressive environment of that cancer. Additionally, it complements the shortcomings of the existing second-generation CAR-T, which makes it a competitive technology for the treatment of solid cancer.
ACT Therapeutics is a Korean bio venture company that has received initial investment through DAYLI Partners, Korea’s leading bio and healthcare venture capital, since its establishment in 2020, and has been recognized for its technology such as receiving pre-series A investment in Samho Green Investment. DAYLI Partners is Korea’s leading bio and healthcare venture capital since its establishment in 2020. At the moment, investment consultations are being held with various securities firms and venture capital companies in order to entice Series A investment.
Brian H. Min, CEO of GenScript ProBio, said, “We are very happy to cooperate with ACT therapeutics in strategic partnership, and we are looking forward to support ACT Therapeutics’ ACT platform as a global partner through our accumulated technology.”
ACT TherapeuticsのCEOであるSeogkyoung-Kongは、次のように述べています。「GenScript ProBioとの戦略的パートナーシップを通じて、ACTプラットフォームがグローバルに出現するための準備が完了しました。 難治性および難治性の固形がんを対象とした治療法の開発を加速します。」
GenScriptProBioについて
GenScript ProBio is a subsidiary of GenScript Biotech Corporation, proactively providing end-to-end CDMO service from drug discovery to commercialization with proactive strategies, professional solutions and efficient processes in cell and gene therapy (CGT), vaccine discovery, biologics discovery and antibody protein drug development to accelerate drug development for customers. GenScript ProBio has established companies in the United States, the Netherlands, South Korea, Shanghai, Hong Kong, Nanjing and other places to serve global customers, and supported customers in the United States, Europe, Asia Pacific and other regions to obtain more than 30 IND approvals.
「コラボレーションによるイノベーション」の使命に向けて、GenScript ProBioは、お客様が生物学的医薬品の開発から商品化までのタイムラインを短縮し、研究開発コストを大幅に削減し、より健康的な未来を築くのを支援することに取り組んでいます。
